Essential Medicines and Patents
Mark Schultz and Jaci McDole recently used DrugPatentWatch to complete a report on recent trends in the latest editions of the […]
Mark Schultz and Jaci McDole recently used DrugPatentWatch to complete a report on recent trends in the latest editions of the […]
We prefer simple flat-rate unrestricted subscriptions — we’ll work on your terms, and with your favorite subscription contract template, to find
Thinking of signing your company up for DrugPatentWatch? Read Post »
Here is a copy of the talk I gave at the recent Marcusevans 13th Portfolio Management and Pipeline Optimization for
Finding and Evaluating Generic Drug Market Entry Opportunities Read Post »
This article not subject to U.S. Copyright. Published 2019 by the American Chemical Society. Noel T. Southall Abstract We report
Freedom of Information Act Access to an Investigational New Drug Application Read Post »
I’ll be giving a talk on Finding and Evaluating Market Entry Opportunities for a Better ROI at the upcoming 13th
Finding and Evaluating Generic Market Entry Opportunities Read Post »
This is a guest post by Shamil Gizatullin, Gowling WLG (International) Inc. shamil.gizatullin@gowlingwlg.com Although it has become harder to obtain
Getting the most out of pharmaceutical patent-term extensions in Russia Read Post »
Don’t wait until the end of the year to start looking for alternatives to your existing business intelligence providers. DrugPatentWatch
Using data from DrugPatentWatch Fred Ledley and his research group at the Center for Integration of Science and Industry at
Government as the First Investor in Biopharmaceutical Innovation Read Post »
In a recent Bloomberg Law article DrugPatentWatch data is used to show a decrease in patent litigation. This likely means
Bloomberg and Drug PatentWatch: A “Perfect Storm” Affecting Generic Drugs Read Post »